Bioscan is a leading supplier of preclinical, nano-tomographic molecular imaging solutions that enable groundbreaking life sciences research. Preclinical imaging uses molecular biomarkers in animals to conduct in vivo studies that generate more relevant, consistent biological data while reducing research cost and complexity. Bioscan’s innovative nuclear (PET & SPECT), 3D optical, ultrasound, X-Ray CT and MRI imaging tools are used by more than 100 leading academic and government research institutions and life sciences companies worldwide to improve their disease, drug discovery and development research. The unique imaging performance enabled by Bioscan‘s patented technologies makes it possible to translate research protocols and results directly from animal models of diseases to human clinical trials, enabling faster, more efficient development of new diagnostics and therapies. Bioscan is a privately held company based in Washington, DC, USA.